// App-Quantinova.ai

3248 : Patient-Reported Experiences during and Following Treatment with Belantamab Mafodotin (Belamaf) for Relapsed/Refractory Multiple Myeloma (RRMM) in the DREAMM-2 Study

Researchers

Presenter

  • Laurie Eliason

Principal Investigators

  • Julia Correll

  • Mona Martin

  • Anna Cardellino

  • Joanna Opalinska

  • Trisha Piontek

  • Boris Gorsh

  • Sandhya Sapra

  • Rakesh Popat

Medical Centers

  • Value Evidence and Outcomes, GlaxoSmithKline, Upper Providence, PA

  • Evidera, Seattle, WA

  • GlaxoSmithKline, Upper Providence, PA

  • GlaxoSmithKline, Philadelphia, PA.

  • University College London Hospitals NHS Trust, London, United Kingdom

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

Biomarkers

  • N/A

Drug/Treatment

  • GSK2857916

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT03525678

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved